Press Releases

Press Releases

These are news releases that are related to our Investor efforts. Releases are listed in chronological order and are archived by year. Sign-up to receive news as it is released using the email and RSS tools.

May 07, 2020
- AGEN1181 (nextgen CTLA-4) +/- balstilimab (anti-PD-1) shows benefit in 70% of patients in Phase 1 - Balstilimab + Zalifrelimab (anti-CTLA-4) achieve 26% response rates in a cohort of 55 patients with advanced cervical cancer - Two INDs filed for AgenTus cell therapy (Allogeneic iNKTs) for cancer
Mar 10, 2020
$15.1M Milestone from HealthCare Royalty Partners LEXINGTON, Mass., March 10, 2020 / PRNewswire / -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of agents designed to activate immune response to cancers, announced the triggering of a $15.1M milestone payment
Feb 06, 2020
LEXINGTON, Mass., Feb. 6, 2020 / PRNewswire / -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of agents designed to activate immune response to cancers, today announced it will hold an Investor Day Thursday, February 20, 2020.
Jan 08, 2020
- AGEN1223 is a novel bi-specific designed to selectively deplete regulatory T cells in the tumor microenvironment - First patient dosed; combinations with other IO agents planned for 2020 LEXINGTON, Mass., Jan. 8, 2020 / PRNewswire / -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with
Nov 12, 2019
LEXINGTON, Mass., Nov. 12, 2019 / PRNewswire / -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies, adoptive cell therapies 1  and cancer vaccines, announced that it will host an R&D Day on November 15, 2019.
Nov 04, 2019
- PD-1 plus CTLA-4 cervical trial completes planned accrual & planned interim analysis - PD-1 cervical trial on track to complete accrual & planned interim analysis by year-end - Four novel I-O antibodies clear INDs & advance into clinical trials - NexGen CTLA-4 (AGEN1181) advances to 3rd cohort;
Aug 28, 2019
FDA acceptance of IND filing for AGEN1223; triggers cash milestone AGEN1223 is a first-in-class bi-specific designed to deplete regulatory T cells in tumor microenvironment LEXINGTON, Mass., August 28, 2019 / PRNewswire / -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a
Aug 21, 2019
Invented by Agenus, licensed to Gilead, GS-1423 is a bi-functional antibody designed to block tumor escape mechanisms Supply supports ongoing Phase 1 of GS-1423 in patients with advanced solid tumors LEXINGTON, Mass., August 21, 2019 / PRNewswire / -- Agenus Inc.
Aug 08, 2019
- FDA acceptance of IND filing for AGEN2373 triggers payment and clears path to begin clinical trials - The payment represents the second milestone in Gilead partnership achieved in 2019 LEXINGTON, Mass., Aug. 8, 2019 / PRNewswire / -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O)
Jul 18, 2019
LEXINGTON, Mass., July 18, 2019 / PRNewswire / -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a broad pipeline of novel clinical and preclinical stage checkpoint antibodies, cell therapies and neoantigen vaccines, today announced the appointment of Don Vidic as Vice President, Head
Jun 13, 2019
LEXINGTON, Mass., June 13, 2019 / PRNewswire / -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune modulating antibodies, cancer vaccines, adjuvants and adoptive cell therapies 1 , invites investors and the general public to attend its annual meeting of stockholders